Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.45 |
| ▸ | TSHR | P16473 | 5/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.45 |
| ▸ | RECQL | P46063 | 2/20 | 0.45 |
| ▸ | CASP1 | P29466 | 2/20 | 0.45 |
| ▸ | TTR | P02766 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL93999 | 0.86 | THRB (1.00) | THRBALDH1A1CYP3A4CA1CA2 | |
| SCHEMBL9453347 | 0.83 | THRB (0.94) | THRBALDH1A1CYP3A4CA1CA2 | |
| Hydrochloric Acid SCHEMBL7755405 | 0.83 | THRB (0.94) | THRBALDH1A1CYP3A4CA1CA2 | |
| Hydrochloric Acid SCHEMBL10336483 | 0.83 | THRB (0.94) | THRBALDH1A1CYP3A4CA1CA2 | |
| SCHEMBL5271617 | 0.83 | THRB (0.94) | THRBALDH1A1CYP3A4CA1CA2 | |
| SCHEMBL95449 | 0.80 | THRB (0.50) | THRBALDH1A1CYP3A4CA1CA2 | |
| Hydrochloric Acid SCHEMBL10336482 | 0.79 | THRB (0.84) | THRBALDH1A1CYP3A4CA1CA2 | |
| SCHEMBL2253709 | 0.79 | TSHR (0.65) | THRBALDH1A1CYP3A4CA1CA2 | |
| SCHEMBL2806380 | 0.79 | TTR (0.65) | THRBALDH1A1CYP3A4CA1CA2 | |
| SCHEMBL22134259 | 0.79 | THRB (0.75) | THRBALDH1A1CYP3A4CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022242743-A1 | HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | 深圳微芯生物科技股份有限公司 | 2022-11-24 | — | — | WO | disclosed |
| EP-3102637-B1 | METHOD FOR PURIFICATION OF ANTIBODIES, ANTIBODY FRAGMENTS OR ENGINEERED VARIANTS THEREOF USING SPECIFIC ANTHRAQUINONE DYE-LIGAND STRUCTURES | BASF SE (DE) | 2018-04-11 | — | — | EP | disclosed |
| US-20160347789-A1 | Method for purification of antibodies, antibody fragments or engineered variants thereof using specific anthraquinone dye-ligand structures | BASF SE (DE) | 2016-12-01 | — | — | US | disclosed |
| US-20160347789-A1 | Method for purification of antibodies, antibody fragments or engineered variants thereof using specific anthraquinone dye-ligand structures | BASF SE (DE) | 2016-12-01 | — | — | US | disclosed |
| EP-2918641-A1 | Method for purification of antibodies, antibody fragments or engineered variants thereof using specific anthraquinone dye-ligand structures | BASF SE (DE) | 2015-09-16 | — | — | EP | disclosed |
| WO-2015117984-A1 | METHOD FOR PURIFICATION OF ANTIBODIES, ANTIBODY FRAGMENTS OR ENGINEERED VARIANTS THEREOF USING SPECIFIC ANTHRAQUINONE DYE-LIGAND STRUCTURES | BASF SE (DE) | 2015-08-13 | — | — | WO | disclosed |
| US-20120016033-A1 | Small Molecule Antagonists of Phosphatidylinositol-3,4,5-Triphosphate (PIP3) and Uses Thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2012-01-19 | — | — | US | disclosed |
| US-7985748-B2 | ALPHA2C adrenoreceptor agonists | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2011-07-26 | — | — | US | disclosed |
| US-7985748-B2 | ALPHA2C adrenoreceptor agonists | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2011-07-26 | — | — | US | disclosed |
| EP-2273500-A1 | Simultaneous two-photon absorption recording-reproduction method, and simultaneous two-photon absorption recording material for use therein | FUJIFILM Corporation (JP) | 2011-01-12 | — | — | EP | disclosed |
| WO-2008100463-A1 | 3,4-DIHYDR0-L,4-BENZ0XAZINE, 3, 4-DIHYDR0-1, 4-BENZOTHIAZINE AND 1,2,3,4-TETRAHYDRO-QUINOXALINE DERIVATIVES AS ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2008-08-21 | — | — | WO | disclosed |
| US-20080039439-A1 | Alpha2C adrenoreceptor agonists | SCHERING CORPORATION | 2008-02-14 | — | — | US | disclosed |
| US-20080039439-A1 | Alpha2C adrenoreceptor agonists | SCHERING CORPORATION | 2008-02-14 | — | — | US | disclosed |
| US-20070093477-A1 | Alpha2C adrenoreceptor agonists | SCHERING CORPORATION AND PHARMACOPEIA DRUG DISCOVERY, INC. | 2007-04-26 | — | — | US | disclosed |
| US-20070093477-A1 | Alpha2C adrenoreceptor agonists | SCHERING CORPORATION AND PHARMACOPEIA DRUG DISCOVERY, INC. | 2007-04-26 | — | — | US | disclosed |
| WO-2007024949-A2 | ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2007-03-01 | — | — | WO | disclosed |
| CN-1701061-A | Novel compounds for inhibiting rotamase enzymes and uses thereof | JERINI AG (DE) | 2005-11-23 | — | — | CN | disclosed |
| WO-2004030664-A2 | NEW COMPOUNDS FOR THE INHIBITION OF UNDESIRED CELL PROLIFERATION AND USE THEREOF | JERINI AG (DE) | 2004-04-15 | — | — | WO | disclosed |
| EP-0093369-B1 | REACTIVE DYES | BAYER AG (DE) | 1986-07-23 | — | — | EP | disclosed |
| EP-0093369-A2 | Reactive dyes | BAYER AG (DE) | 1983-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016033-A1 | Small Molecule Antagonists of Phosphatidylinositol-3,4,5-Triphosphate (PIP3) and Uses Thereof | PIP5K1A, PIP5K1B, PIP4K2A | THRB 1832/4885ALDH1A1 4808/4885CYP3A4 4658/4885 |
| US-20070093477-A1 | Alpha2C adrenoreceptor agonists | ADRA2C, ADRB2, ADRA2A | THRB 92/4885ALDH1A1 915/4885CYP3A4 2086/4885 |
| US-20160347789-A1 | Method for purification of antibodies, antibody fragments or engineered variants thereof using specific anthraquinone dye-ligand structures | ANTXR2, FCGR3B, IGLV6-57 | THRB 3915/4885ALDH1A1 1699/4885CYP3A4 2751/4885 |
| US-20080039439-A1 | Alpha2C adrenoreceptor agonists | ADRA2C, ADRB2, ADRA2A | THRB 92/4885ALDH1A1 915/4885CYP3A4 2086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.